# The Role of Ruxolitinib in Secondary Acute Myelogenous Leukemia Evolving From Myeloproliferative Neoplasm

> **NCT03558607** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Seoul National University Hospital** · enrollment: 17 (estimated)

## Conditions studied

- Secondary Acute Myelogenous Leukemia Evolving From Myeloproliferative Disorder

## Interventions

- **DRUG:** Ruxolitinib

## Key facts

- **NCT ID:** NCT03558607
- **Lead sponsor:** Seoul National University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-05-17
- **Primary completion:** 2022-04-30
- **Final completion:** 2024-08-31
- **Target enrollment:** 17 (ESTIMATED)
- **Last updated:** 2020-03-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03558607

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03558607, "The Role of Ruxolitinib in Secondary Acute Myelogenous Leukemia Evolving From Myeloproliferative Neoplasm". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT03558607. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*